Skip to main content
SpringerLink
Log in

Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Measuring tumor-specific trends in incidence is necessary to elucidate tumor-type contribution to overall cancer burden in the US population. Recently, there have been conflicting reports concerning the incidence of oligodendrogliomas (OD) and anaplastic oligodendrogliomas (AOD). Therefore, our goal was to examine trends in OD and AOD incidence and survival by age, gender and race. Data was analyzed from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2013. Age-adjusted incidence rates per 100,000 person-years with 95% confidence intervals (CI) and annual percent changes (APCs) with 95% CI were calculated for OD and AOD by age, sex and race. Survival rates were calculated for age, sex and race using a subset of the CBTRUS data. OD and AOD incidence peaked at 36–40 and 56–60 years, respectively. AOD:OD ratio increased up to age 75. Overall, OD and AOD incidence decreased [OD: APC −3.2 (2000–2013), AOD: −6.5 (2000–2007)]. OD incidence was highest in Whites but decreased significantly (2000–2013: APC −3.1) while incidence in Black populations did not significantly decrease (2000–2013: APC −1.6). Survival rates decreased with advancing age for OD, while persons aged 0–24 had the lowest survival for AOD. The current study reports a decrease in overall OD and AOD incidence from 2000 to 2013. Furthermore, AOD makes up an increasing proportion of oligodendroglial tumors up to age 75. Lower AOD survival in 0–24 years old may indicate molecular differences in pediatric cases. Thus, surveillance of tumor-specific trends by age, race and sex can reveal clinically relevant variations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gittleman HR, Ostrom QT, Rouse CD, Dowling JA, de Blank PM, Kruchko CA, Elder JB, Rosenfeld SS, Selman WR, Sloan AE, Barnholtz-Sloan JS (2015) Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121(1):102–112

    Article  PubMed  Google Scholar 

  2. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18(Suppl 1):i1–i50

    Article  PubMed  Google Scholar 

  3. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–i56

    Article  PubMed  PubMed Central  Google Scholar 

  4. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636–645

    Article  CAS  PubMed  Google Scholar 

  5. van den Bent M, Chinot O-L, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 5(2):128–138

    PubMed  PubMed Central  Google Scholar 

  6. Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97(5):1276–1284

    Article  PubMed  Google Scholar 

  7. Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, Lee M, Chen P, Wrensch M (2000) Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer 88(10):2342–2349

    Article  CAS  PubMed  Google Scholar 

  8. Burger PC (2002) What is an oligodendroglioma? Brain Pathol 12(2):257–259

    Article  PubMed  Google Scholar 

  9. McCarthy BJ, Propp JM, Davis FG, Burger PC (2008) “Time trends in oligodendroglial and astrocytic tumor incidence.” Neuroepidemiology 30(1):34–44

    Article  PubMed  Google Scholar 

  10. Arora RS, Alston RD, TOB Eden, Estlin EJ, Moran A, Geraci M, Birch JM (2010) Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer 46(9):1607–1616

    Article  PubMed  Google Scholar 

  11. Overview of the Seer Program. In: National Cancer Institute. http://seer.cancer.gov/about/overview.html. Accessed 9 Apr 2017

  12. Number of Persons by Race and Hispanic Ethnicity for SEER Participants - SEER Registries. In: National Cancer Institute. http://seer.cancer.gov/registries/data.html. Accessed 9 Apr 2017

  13. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA 66(1):7–30

    PubMed  Google Scholar 

  14. Little MP, Rajaraman P, Curtis RE, Devesa SS, Inskip PD, Check DP, Linet MS (2012) Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 344:e1147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Barchana M, Margaliot M, Liphshitz I (2012) Changes in brain glioma incidence and laterality correlates with use of mobile phones–a nationwide population based study in Israel. Asian Pac J Cancer Prev 13(11):5857–5863

    Article  PubMed  Google Scholar 

  16. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60(5):443–456

    Article  PubMed  Google Scholar 

  17. Arora RS, Alston RD, TOB. Eden, Estlin EJ, Moran A, Birch JM (2009) Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11(4):403–413

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61(3):215–259

    Article  PubMed  Google Scholar 

  19. Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59(9):1617–1625

    Article  CAS  PubMed  Google Scholar 

  20. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K (1991) Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74(1):27–37

    Article  CAS  PubMed  Google Scholar 

  21. Jung K-W, Yoo H, Kong H-J, Won Y-J, Park S, Lee SH (2012) Population-based survival data for brain tumors in Korea. J Neurooncol 109(2):301–307

    Article  PubMed  Google Scholar 

  22. Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S, and EUROCARE Working Group (2012) Survival of European patients with central nervous system tumors. Int J cancer 131(1):173–185

    Article  CAS  PubMed  Google Scholar 

  23. Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C (2011) Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 13(10):1099–1106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62(5):530–537

    Article  PubMed  Google Scholar 

  25. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA (2005) Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 109(4):387–392

    Article  PubMed  Google Scholar 

  26. Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S (2013) 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol 15(6):775–782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479

    Article  CAS  PubMed  Google Scholar 

  28. Curry WT, Carter BS, Barker FG (2010) Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988–2004. Neurosurgery 66(3):427–438

    Article  PubMed  Google Scholar 

  29. Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 98(3):603–609

    Article  PubMed  Google Scholar 

  30. Tseng M-Y, Tseng J-H, Merchant E (2006) Comparison of effects of socioeconomic and geographic variations on survival for adults and children with glioma. J Neurosurg 105(4 Suppl):297–305

    PubMed  Google Scholar 

  31. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109

    Article  PubMed  PubMed Central  Google Scholar 

  32. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C (2009) Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol 11(3):311–317

    Article  PubMed  PubMed Central  Google Scholar 

  33. Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage C-A, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre J-Y, Figarella-Branger D, and For POLA Network (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634

    Article  PubMed  Google Scholar 

  34. Cahill DP, Sloan AE, Nahed BV, Aldape KD, Louis DN, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 125(3):531–549

    Article  PubMed  Google Scholar 

  35. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, and Feuerstein BG (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14(9):842–853

    Article  CAS  PubMed  Google Scholar 

  36. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

    Article  PubMed  Google Scholar 

  37. Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS (2016) “Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). J Neurooncol 130:31–42

    Article  PubMed  Google Scholar 

Download references

Funding

Funding for CBTRUS was provided by the Centers for Disease Control and Prevention (CDC) under Contract No. 200-2016-M-90304, The Sontag Foundation, Genentech, Novocure, Celldex, AbbVie, along with the Musella Foundation, Voices Against Cancer, Elekta, and the Zelda Dorin Tetenbaum Memorial Fund, as well as private and in kind donations.

Author information

Author notes

    Authors and Affiliations

    1. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

      Rebecca L. Achey & Vishesh Khanna

    2. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Wearn 152, Cleveland, OH, 44106-5065, USA

      Quinn T. Ostrom, Carol Kruchko & Jill S. Barnholtz-Sloan

    3. Central Brain Tumor Registry of the United States, 244 East Ogden Ave, Suite 116, Hinsdale, IL, 60521, USA

      Quinn T. Ostrom, Carol Kruchko & Jill S. Barnholtz-Sloan

    Authors
    1. Rebecca L. Achey
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Vishesh Khanna
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Quinn T. Ostrom
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Carol Kruchko
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jill S. Barnholtz-Sloan
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jill S. Barnholtz-Sloan.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Ethical approval

    All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board at University Hospitals Case Medical Center. For this type of study, formal consent was not required.

    Informed consent

    This was a retrospective study using de-identified national cancer registries. Thus, formal consent was not required.

    Additional information

    Rebecca L Achey and Vishesh Khanna contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOCX 13 KB)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Achey, R.L., Khanna, V., Ostrom, Q.T. et al. Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. J Neurooncol 133, 17–25 (2017). https://doi.org/10.1007/s11060-017-2414-z

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11060-017-2414-z

    Keywords

    Search

    Navigation